Evidence map›Paper›PMID 33068336›Full record

ArticleCancer medicine2020

Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.

Feili Chen, Diwen Pang, Hanguo Guo, Qiuxiang Ou, Xue Wu, Xinmiao Jiang, Xiaojuan Wei, Sichu Liu, Ling Huang, Zhanli Liang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Updates of primary central nervous system lymphoma.Therapeutic advances in hematology · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. AI-enhanced simultaneous multiparametricEuropean journal of nuclear medicine and molecular imaging · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Feili ChenLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Diwen PangLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Hanguo GuoLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Qiuxiang OuTranslational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada.ORCID 0000-0002-2961-2057
Xue WuTranslational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada.
Xinmiao JiangLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Xiaojuan WeiLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Sichu LiuLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Ling HuangLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Zhanli LiangLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.
Dong ZhouDepartment of Neurosurgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Wenyu LiLymphoma Division, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.ORCID 0000-0002-6444-7149
Guangdong Academy of Medical Sciences · CNOntario Power Generation · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ibrutinib-based combination therapy with high-dose methotrexate (HD-MTX) has recently shown clinical activity against relapse/refractory (R/R) primary central nervous system lymphoma (PCNSL). Herein, we report our real-world experience of treating 11 newly diagnosed PCNSL patients with the ibrutinib/MTX combination. HD-MTX was given at 3.5 g/m

Indexed as

Off-Label UseAdenineAdultAgammaglobulinaemia Tyrosine KinaseAgedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsDisease ProgressionFemaleHumansLymphomaMaleMethotrexateMiddle AgedPiperidinesProgression-Free SurvivalAdenineAgammaglobulinaemia Tyrosine KinaseBTK protein, humanibrutinibMethotrexatePiperidinesProtein Kinase Inhibitors

Identifiers

PMID33068336
PMCPMC7666749
OpenAlexW3092792491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.